Patisiran

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

Retrieved on: 
Monday, November 13, 2023
Alnylam Pharmaceuticals, Food, LLP, Cardiomyopathy, Amyloidosis, Patisiran, ATTR, FDA, New Drug Application, CRL, Symantec Endpoint Protection, Shanda, News, Pomerantz

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).
  • The investigation concerns whether Alnylam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)

Retrieved on: 
Thursday, November 9, 2023
Alnylam Pharmaceuticals, Telephone, Patisiran, Food, Cardiomyopathy, Amyloidosis, Patient, ATTR, FDA, New Drug Application, CRL, Symantec Endpoint Protection, Shanda, News

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

Retrieved on: 
Wednesday, November 8, 2023
FDA, CM, Food, ATTR, Cardiomyopathy, Alnylam Pharmaceuticals, Symantec Endpoint Protection, Fraud, News, Patisiran, CRL, ALNY, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.

Key Points: 
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Alnylam investors.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws

Retrieved on: 
Tuesday, November 7, 2023
FDA, CM, Food, ATTR, Cardiomyopathy, Symantec Endpoint Protection, News, Patisiran, Law, CRL, ALNY, New Drug Application, Vincent Wong, Amyloidosis, Crown Law Office (New Zealand), Patient, Shanda, Pharmaceutical industry, Alnylam Pharmaceuticals

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:

Key Points: 
  • NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:
    The Law Offices of Vincent Wong announce that an investigation has commenced into Alnylam and certain of its officers and directors regarding potential securities fraud.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • If you suffered a loss on your investment in Alnylam, contact us about potential recovery by using the link below.
  • is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)

Retrieved on: 
Monday, November 6, 2023
FDA, CM, Food, ATTR, Alnylam Pharmaceuticals, Cardiomyopathy, Telephone, Symantec Endpoint Protection, News, Patisiran, CRL, Levi, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

Retrieved on: 
Sunday, November 5, 2023
FDA, Food, ATTR, Cardiomyopathy, Alnylam Pharmaceuticals, Symantec Endpoint Protection, News, Patisiran, CRL, Pomerantz, LLP, New Drug Application, Amyloidosis, Shanda, Private investigator

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).

Key Points: 
  • NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY).
  • The investigation concerns whether Alnylam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

Retrieved on: 
Thursday, November 2, 2023
FDA, CM, Food, ATTR, Cardiomyopathy, Alnylam Pharmaceuticals, Symantec Endpoint Protection, Fraud, News, Patisiran, CRL, ALNY, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.

Key Points: 
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Alnylam investors.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)

Retrieved on: 
Wednesday, November 1, 2023
FDA, CM, Food, ATTR, Alnylam Pharmaceuticals, Cardiomyopathy, Telephone, Symantec Endpoint Protection, News, Patisiran, CRL, Levi, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) concerning possible violations of federal securities laws.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws

Retrieved on: 
Tuesday, October 31, 2023
FDA, CM, Food, ATTR, Cardiomyopathy, Symantec Endpoint Protection, News, Patisiran, Law, CRL, ALNY, New Drug Application, Vincent Wong, Amyloidosis, Crown Law Office (New Zealand), Patient, Shanda, Pharmaceutical industry, Alnylam Pharmaceuticals

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:

Key Points: 
  • NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:
    The Law Offices of Vincent Wong announce that an investigation has commenced into Alnylam and certain of its officers and directors regarding potential securities fraud.
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • If you suffered a loss on your investment in Alnylam, contact us about potential recovery by using the link below.
  • is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

Retrieved on: 
Monday, October 30, 2023
FDA, CM, Food, ATTR, Cardiomyopathy, Alnylam Pharmaceuticals, Symantec Endpoint Protection, Fraud, News, Patisiran, CRL, ALNY, New Drug Application, Amyloidosis, Patient, Shanda, Pharmaceutical industry

Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.

Key Points: 
  • Following this news, Alnylam’s stock price fell by $2.53 per share, or approximately 2% to close at $165.29 per share.
  • Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Alnylam investors.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.